Financial Data and Key Metrics Changes - The company's full-year revenue grew by 10.3% year-on-year, with significant increases in adjusted net profit and EBITDA [1][10] - The leverage ratio decreased from 4x in 2024 to 3.045x in 2025, indicating improved financial health [1][45] - The adjusted EBITDA margin was reported at 14.3%, with a net profit growth rate of 22.7% [10][12] Business Segment Data and Key Metrics Changes - Swisse's revenue exceeded HKD 1 billion, achieving number one position in both Mainland China and Australia [2] - The BNC business saw a 20% growth, with the super premium infant formula segment growing by 17.12% [3][12] - The PNC business accounted for 15% of total revenue, marking a new milestone, with pet supplements achieving double-digit growth [3][12] Market Data and Key Metrics Changes - China remains the largest market, contributing over 70% of revenue with a growth of 17.5% [13] - North America accounted for 12.1% of revenue, growing by 7.5%, while the ANZ market decreased by 20.2% due to strategic adjustments [14][15] - Other markets grew by 14.7% year-on-year, indicating new growth momentum [15] Company Strategy and Development Direction - The company plans to continue investing in its three business segments to enhance shareholder value and maintain a strong cash flow [4][29] - Focus on systematic innovation and consumer insights to drive product development and market expansion [6][9] - The strategy includes localization of supply chains and expansion into high-growth channels, particularly in Southeast Asia [29][30] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, emphasizing the importance of innovation and market adaptation [28][31] - The company aims to maintain a stable SG&A ratio while continuing to invest in new channels and product categories [65] - Management acknowledged challenges from tariffs and market adjustments but remains optimistic about future performance [22][75] Other Important Information - The company maintained a dividend payout ratio of 30%, with a total dividend of HKD 0.35 per share [4][11] - The company has made significant strides in sustainability, achieving high rankings in ESG metrics [28] Q&A Session Summary Question: What has contributed to the strong growth of IMF? - Management highlighted the strong formula of the upgraded IMF and the effective market launch strategies as key factors for growth [49][50] Question: What is the expansion plan for the Southeast Asian market? - The company is focusing on Thailand, Indonesia, Singapore, and Vietnam, leveraging product innovation and local consumer insights [54][55] Question: What is the outlook for the Douyin channel and marketing expenses? - Management views Douyin as a critical channel for consumer education and sales, with plans to maintain a stable SG&A ratio while investing in new channels [60][65]

Financial Data and Key Metrics Changes - The company's full-year revenue grew by 10.3% year-on-year, with significant increases in adjusted net profit and EBITDA [1] - The leverage ratio has been reduced from 4x in 2024 to 3.045x in 2025 [1][45] - Adjusted EBITDA margin is reported at 14.3%, with adjusted net profit margin at 4.6% and net profit growth rate at 22.7% [10][32] Business Segment Data and Key Metrics Changes - Swisse revenue sales exceeded HKD 1 billion, achieving number one position in both Mainland China and Australia [2] - The BNC business saw a 20% growth, with the super premium infant formula segment achieving 17.12% growth [3] - The PNC business accounted for 15% of total revenue, marking a new milestone [3] Market Data and Key Metrics Changes - China remains the largest market, accounting for over 70% of revenue with a growth of 17.5% [13] - North America is the second largest market, contributing 12.1% of revenue with a 7.5% year-on-year growth [14] - The ANZ market accounted for 11% of revenue but saw a decrease of 20.2% due to strategic adjustments [14] Company Strategy and Development Direction - The company plans to continue investing in its three business segments to return value to shareholders and consumers [4] - Focus on systematic innovation and consumer insights to drive growth, with new product launches across various segments [6][9] - Emphasis on expanding presence in high-growth channels, including Douyin and new retail [29] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth momentum for 2026, with a focus on sustainable growth and healthy profitability [28][31] - The company aims to strengthen its leadership in core markets while expanding into new territories [29][30] - Management acknowledged challenges from tariffs and market adjustments but remains optimistic about future performance [19][22] Other Important Information - The company maintained a dividend payout ratio of 30%, with a total dividend of HKD 0.35 per share [4][11] - The company has made significant strides in sustainability efforts, achieving high rankings in ESG metrics [28] Q&A Session Summary Question: What has been done right for IMF growth and market share? - Management highlighted strong product formulation and effective market strategies, leading to over 25% growth in IMF [50] - The company has gained market share from competitors, particularly in the super premium segment, increasing from 17.1% to 19.5% [53] Question: What are the expansion plans for the Southeast Asian market? - The company is focusing on Thailand, Indonesia, Singapore, and Vietnam, leveraging product innovation and local consumer insights [55] Question: Insights on Douyin channel profitability and marketing expenses? - Management views Douyin as a crucial channel for consumer education and sales, balancing investments across various channels [61][62] - Marketing expenses are expected to remain stable while continuing to invest in new channels and product categories [66]

Financial Data and Key Metrics Changes - The company's full-year revenue grew by 10.3% year-on-year, with significant increases in adjusted net profit and EBITDA [1] - The leverage ratio decreased from 4x in 2024 to 3.045x in 2025, indicating improved financial health [1][41] - Adjusted EBITDA margin was reported at 14.3%, while adjusted net profit margin was 4.6%, with net profit growth at 22.7% [8][10] Business Segment Data and Key Metrics Changes - Swisse revenue exceeded HKD 1 billion, achieving number one position in both Mainland China and Australia, with double-digit growth in China [2] - The BNC business segment saw a 20% growth, with super premium infant formula segment growing by 17.12% [3][10] - The PNC business accounted for 15% of total revenue, marking a new milestone, with pet supplements achieving double-digit growth [3][10] Market Data and Key Metrics Changes - China remains the largest market, contributing over 70% of revenue with a growth rate of 17.5% [11] - North America accounted for 12.1% of revenue, growing by 7.5%, while the ANZ market decreased by 20.2% due to strategic adjustments [12][11] - Other markets grew by 14.7% year-on-year, contributing to overall revenue growth [13] Company Strategy and Development Direction - The company plans to continue investing in its three business segments to enhance shareholder value and maintain a strong cash flow [4] - Focus on systematic innovation and consumer insights to drive growth, with new product launches across various segments [5][6] - The strategy includes expanding into high-growth channels and markets, particularly in Southeast Asia [49][26] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth momentum for 2026, emphasizing the importance of innovation and market adaptation [25][28] - The company aims to maintain its leadership position in the Chinese market while expanding its presence in international markets [26][27] - Management acknowledged challenges from tariffs and market adjustments but remains optimistic about future profitability [20][21] Other Important Information - The company maintained a dividend payout ratio of 30%, with a total dividend of HKD 0.35 per share [4][9] - Significant improvements in cash flow conversion, with 88% of operating cash flow converted from adjusted EBITDA [9][38] - The company is committed to sustainability and ESG efforts, achieving high rankings in relevant indices [25] Q&A Session Summary Question: What has contributed to the strong growth in IMF? - Management highlighted the strong formula of the product and effective market strategies, with a focus on early-stage education and e-commerce expansion [43][44] Question: What is the expansion plan for the Southeast Asian market? - The company plans to leverage product innovation from the Chinese market and adapt to local consumer demands in Thailand, Indonesia, Singapore, and Vietnam [48][49] Question: How does the company view the profitability of the Douyin channel? - Management sees Douyin as a crucial channel for consumer education and sales, emphasizing a balanced approach to investment in various channels [52][53]

Group 1 - The current trend in China's health consumption market can be summarized as "decentralization," indicating a shift in consumer demographics, scenarios, and decision-making processes, which raises the requirements for brand organization and product structure [1] - The traditional growth model driven by a single brand or product is becoming increasingly unsustainable, with long-term competitiveness now relying on a brand system that addresses various consumer life stages and health needs [1] - Swisse's "Mega Brand" strategy is a proactive response to this trend, focusing on building a clear brand hierarchy around the main brand to achieve systematic coverage of different consumer groups and consumption depths [1] Group 2 - From an investment perspective, the value of the Mega Brand lies not in short-term growth speed but in sustainable growth and cyclical resilience, with brands that possess matrix capabilities showing higher visibility and more controllable fluctuations in performance [2] - For the health group, Swisse represents not just a standout single brand but a growth paradigm that aligns with the current health consumption phase, emphasizing a structure-driven growth model rather than a single-point-driven approach [2]

Core Insights - Swisse has transformed from a cross-border e-commerce newcomer to a leading brand in China's health market over the past decade, showcasing a successful case of international brand localization [2][3][4]. Group 1: Strategic Evolution - Swisse's journey in China can be divided into three key phases: - Phase 1 (2016-2018): Capitalized on the rise of cross-border e-commerce and positioned itself as a trendy brand targeting younger consumers, successfully entering the oral beauty segment [6][7]. - Phase 2 (2019-2022): Transitioned to localization, launching sub-brands like Little Swisse and Swisse Me to meet diverse consumer needs, while becoming the top international nutrition brand in China's online market [8][9]. - Phase 3 (2023-present): Focused on strategic upgrades and multi-brand collaboration, achieving a 15.7% year-on-year growth in the first three quarters of 2025, contributing to 70.6% of the group's sales [9][11]. Group 2: Underlying Growth Logic - Swisse's growth is driven by a deep understanding of local consumer needs, combining global research capabilities with local health trends, and establishing a strong scientific brand image [11][13]. - The brand's operational model includes a localized team for quick decision-making and marketing strategies that resonate with local consumers, utilizing platforms like Xiaohongshu and Douyin [13]. Group 3: Brand Strategy and Market Positioning - Swisse has upgraded its brand strategy to "Swisse Mega Brand," creating a product matrix that covers all life stages, with the main brand serving as a stabilizing force while sub-brands target specific consumer segments [15][20]. - The brand's performance during the 2025 Double Eleven shopping festival demonstrated its market dominance, with Swisse maintaining the top sales in categories like fish oil and oral beauty [20][21]. Group 4: Future Growth Strategies - Looking ahead, Swisse aims to deepen its core product offerings while exploring new market opportunities in areas like cardiovascular health and immune support, aligning with societal trends such as aging and lifestyle-related health concerns [24][29]. - The company has established a robust infrastructure for future growth, including a localized team, comprehensive channel touchpoints, and a scientific approach to product development [30].

Summary of H&H Holdings Conference Call Industry Overview - The global dietary supplement (VDS) market is experiencing steady growth, with a market size of approximately $132.4 billion in 2023 and an annual growth rate of 4%-5% [2][7] - The Chinese health supplement market is growing significantly faster than the global average, with a compound annual growth rate (CAGR) of 8%-9% from 2010 to 2023, increasing from over 70 billion yuan to around 224 billion yuan [2][7] - The health supplement industry in China benefits from aging demographics and new consumption trends, with online sales channels accelerating, rising to 60% post-pandemic [2][9] Company Insights - H&H Holdings has transformed into a health supplement company primarily focused on adult health, with over 90% of Swisse brand revenue coming from online channels, maintaining a market share of 7%-8% [2][11] - The company has diversified its brand matrix by launching new brands targeting teenagers, children, and pets, such as Swisse Me, Little Swisse, and Plus [2][11] - H&H Holdings is actively expanding its oral beauty product line, including high-margin products like super light bottles and anti-sugar pills, which are expected to enhance profitability [2][14] Financial Performance and Projections - H&H Holdings is expected to optimize interest expenses by approximately 100 million yuan in 2025 through the replacement of high-interest dollar debt with domestic low-interest loans, which will directly enhance profits [2][5][21] - The company anticipates an adjusted net profit of around 700 million yuan in 2025, representing a nearly 30% year-on-year growth, indicating a turning point in its fundamentals [2][23] - The company’s revenue structure has shifted, with a 24%-25% decline in milk powder revenue in 2024 due to regulatory changes, but a recovery of 44% in the first quarter of 2025 is expected [2][13][14] Market Strategy and Brand Development - H&H Holdings is focusing on the Southeast Asian market for expansion, aiming to replicate the success of the Swisse brand in this region [2][20][27] - The company’s management team has extensive experience in fast-moving consumer goods (FMCG) and foreign investment, which supports strategic clarity and revenue stability across different phases [2][16] - The Swisse brand has expanded its core family nutrition series to include oral beauty products, which are expected to drive future growth [2][15] Risk Assessment - The company has a high level of goodwill, approximately 7.8 billion yuan, primarily concentrated in the Swisse and pet brands, which are performing well with no significant impairment risks [2][22] - Legal issues are not expected to significantly impact the company's financial status, as past experiences suggest a favorable outcome in similar cases [2][25] Conclusion - H&H Holdings is positioned for significant growth in the health supplement market, with a strong focus on online sales and brand diversification. The company’s financial outlook is positive, with expectations of increased profitability and market expansion, particularly in Southeast Asia. The management's strategic decisions and market positioning provide a solid foundation for future growth [2][26][27]